[1] FROMM M F， KIM R B. Drug Transporters. Erlangen：Springer Verlag Berlin Heidelberg， 2011：5.
[2] HE X， WU W H， OUYANG D S， et al. Progress in transporters of ABCC2. Chin Pharm J(中国药学杂志)， 2007， 42(23)：1764-1767.
[3] MAXEREEUW R， RUSSEL F. Screening for the role of transporters in hepatic and renal drug handling . Drug Discov Today， 2004， 1(4)：357-364.
[4] SHITARA Y， HORIEA T， SUGIYAMA Y. Transporters as a determinant of drug clearance and tissue distribution . Eur J Pharm Sci， 2006， 27(5)：425-446.
[5] SEKINE T， WATANABE N， HOSOYAMADA M， et al. Expression cloning and characterization of a novel multispecific organic anion transporter . J Biol Chem， 1997， 272(30)：18526-18529.
[6] SWEET D H， WOLFF N A， PRITCHARD J B. Expression cloning and characteri-zation of rOAT1. The basolateral organic anion transporter in rat kidney . J Biol Chem， 1997， 272(48)：30088-30095.
[7] KOJIMA R， SEKINE T， KAWACHI M， et al. Immunolocalization of multispecific organic anion transporters， OAT1， OAT2， and OAT3， in rat kidney . J Am Soc Nephrol， 2002， 13(4)：848-857.
[8] SEKINE T， CHA S H， TSUDA M，et al. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. Febs Lett，1998，429（2）：179-182.
[9] MINEMATSU T， HASHIMOTO T， AOKI T， et al. Role of organic anion trans-porters in the pharmacokinetics of zonampanel， an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist， in rats . Drug Metab Dispos， 2008， 36(8)：1496-1504.
HAN Y H， BUSLER D， HONG Y， et al. Transporter studies with the 3-O-sulfate-conjugate of 17 alpha-ethinylestradiolAssessment of human kidney drug transpor-ters . Drug Metab Dispos， 2010， 38(7)：1064-1071.
MEYER Z U， SCHWABEDISSEN H E， KIM R B. Hepatic OATP1B transporters and nuclear receptors PXR and CARInterplay， regulation of drug disposition genes， and single nucleotide polymorphisms . Mol Pharm， 2009， 6(6)：1644-1661.
SEKINE T， MIYAZAKI H， ENDOU H. Molecular physiology of renal organic anion transporters . Am J Physiol Renal Physiol， 2006， 290(2)：251-261.
HIRANO M， MAEDA K， SHITARA Y， et al. Contribution of OATP2(OATP1B1) and OATP8(OATP1B3) to the hepatic uptake of pitavastatin in humans . J Pharmacol Exp Ther， 2004， 311(1)：139-146.
YAMASHIRO W， MAEDA K， HIROUCHI M， et al. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan， a selective antagonist of the angiotensin Ⅱ AT 1-receptor， in humans . Drug Metab Dispos， 2006， 34(7)：1247-1254.
GRUNDEMANN D， GORBOULEV V， GAMBARYAN S， et al. Drug excretion mediated by a new prototype of polyspecific transporter . Nature， 1994， 372(6505)：549-552.
STEPHEN H. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics . Toxicol Appl Pharm， 2005， 204(3)：309-319.
KATHLEEN M， GIACOMINI， SHIEW M H， et al. Membrane transporters in drug development . Nat Rev Drug Discov， 2010， 9(3)：215-236.
TOMOKO N F， DAVID R. Renal excretion of emtricitabine IEffects of orga-nic anion， organic cation， and nucleoside transport inhibitors on emtricitabine excretion . J Pharm Sci， 2008， 97(12)：5401-5410.
FUNK C， PONELLE C， SCHEUERMANN G， et al. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxi-cityIn vivo and in vitro interaction at the canalicular bile salt export pump(Bsep) in the rat. Mol Pharmacol， 2001， 59(3)：627-635.
FATTINGER K， FUNK C， PANTZE M， et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pumpA potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther， 2001， 69（4）：223-231.
MILNE R W， LARSEN L A， JORGENSEN K L，et al. Hepatic disposition of fex-ofenadine：influence of the transport inhibitors erythromycin and dibromosulpho-thalein . Pharm Res， 2000， 17(12)：1511-1515.
SPEEG K V， MALDONAD A L. Effect of the nonimmunosuppressive cycolspo-rin analog SDZ PSC-833 on colchicines and doxorubicin biliary secretion by the rat in vivo . Cancer Chemother Pharmacol， 1994， 34(2)：133-136.
BARDELMEIJER H A， OUWEHAND M， BEIJNEN J H，et al. Efficacy of novel p-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice . Invest New Drugs， 2004， 22(3)：219-229.
ZUYLEN L V， VERWEIJ J， NOOTER K. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans . Clin Cancer Res， 2000， 6：2598-2603.
JAGER W， GEHRING E， HAGENAUER B，et al. Biliary excretion of flavopiri-dol and its glucuronides in the isolated perfused rat liverRole of multidrug resistance protein 2(Mrp2) . Life Sci， 2003， 73(2)：2841-2854.
HASEGAWA M， KUSUHARA H， ADACHI M， et al. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide . J Am Soc Nephrol， 2007， 18(1)：37-45.
IEIRI I， HIGUCHI S， SUGIYAMA Y. Genetic polymorphisms of uptake(OATP1 B1， 1B3) and efflux (MRP2， BCRP) transportersImplications fornter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs . Expert Opin Drug Metab Toxicol， 2009， 5(7)：703-729.
FRANKE R M， SCHERKENBACH L A， SPARREBOOM A. Pharmacogenetics of the organic anion transporting polypeptide 1A2 . Pharmacogenomics， 2009， 10(3)：339-344.
NISHIZATO Y， IEIRI I， SUZUKI H， et al. Polymorphisms of OATP-C(SLC21A6) and OAT3(SLC22A8) genesConsequences for pravastatin pharmacokinetics . Clin Pharmacol Ther， 2003， 73(6)：554-565.
HORIKAWA M， KATO Y， TYSON C A， et al. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agentsProbenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites . Drug Metab Pharmacokinet， 2002， 17(1)：23-33.
BAUER L A， HORN J R， PETTIT H. Mixed-effect modeling for detection and evaluation of drug interactionsDigoxin-quinidine and digoxin-verapamil combi-nations . Ther Drug Monit， 1996， 18(1)：46-52.
KODAWARA T， YANO I，MASUDA S， et al. Interaction of azole antifungal agents with human P-glycoprotein expressed in a kidney epithelial cell line， LLC-PK1 . Xenobiol Metabol Dispos， 2001， 16(1)：5-11.
AYRTON A， MORGAN P. Role of transport proteins in drug absorption， distribution and excretion . Xenobiotica， 2001， 31(8-9)：469-497.
SAKURAI Y， MOTOHASHI H， UEO H， et al. Expression levels of renal organic anion transporters(OATs) and their correlation with anionic drug excretion in patients with renal diseases . Pharm Res， 2004， 21(1)：61-67.
ANABEL B， VILLAR S R， PICENA J C， et al. Expression of rat renal corti-cal OAT1 and OAT3 in response to acute biliary obstruction . Hepatology， 2006， 43(5)：1092-1100.
BRCAKOVA E， FUKSA L， CERMANOVA J， et al. Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats . Biol Pharm Bull， 2009，32(12)：1978-1985.
URAKAMI Y， NAKAMURA N， TAKAHASHI K， et al. Gender differences in expression of organic cation transporter OCT2 in rat kidney . FEBS Lett， 1999， 461(3)：339-342.
MORRIS M E， LEE H J， PREDKO L M. Gender differences in the membrane transporter of endogenous and exogenous compounds . Pharmacol Rev， 2003， 55(2)：229-240.
MERINO G， VAN HERWAARDEN A E， WAGENAAR E， et al. Sex dependent expression and activity of the ATP binding cassette transporter breast cancer resistance protein(BCRP/ABCG2) in liver. Mol Pharmacol， 2005， 67(5)：1765-1771.
PAHLMAN I， ANDERSSON S， GUNNARSSON K， et al. Extensive biliary excretion of the sulfasalazine analogue， susalimod， but different concentrations in various animal species correlating to species-specific hepatobiliary toxicity . Pharmacol Toxicol， 1999， 85(5)：123-129.
LAVE T， PORTMANN R， SCHENKER G， et al. Inter-species pharmacokinetic comparisons and allometric scaling of napsagatran， a low molecular weight thro-mbin inhibitor . J Pharm Pharmacol， 1999， 51(1)：85-91.
KELLY A R， VSEVOLOD K， JASMINDER S. Hepatobiliary disposition in pri-mary cultures of dog and monkey hepatocytes . Mol Pharm， 2006， 3(3)：266-274.